Gliomas represent the most commonly occurring tumors in the central nervous system and account for approximately 80% of all malignant primary brain tumors. With a high malignancy and recurrence risk, the prognosis of high-grade gliomas is poor, with a mean survival time of 12–18 months. While contrast-enhanced MRI serves as the standard diagnostic imaging modality for gliomas, it faces limitations in the evaluation of recurrent gliomas, failing to distinguish between treatment-related changes and tumor progression, and offers no direct therapeutic options. Recent advances in imaging modalities have attempted to address some of these limitations, including positron emission tomography (PET), which has demonstrated success in delineating tumor margins and guiding the treatment of recurrent gliomas. Additionally, with the advent of theranostics in nuclear medicine, PET tracers, when combined with therapeutic agents, have also evolved beyond a purely diagnostic modality, serving both diagnostic and therapeutic roles. This review will discuss the growing involvement of theranostics in diagnosing and treating recurrent gliomas and address the associated impact on quality of life and functional recovery.
胶质瘤是中枢神经系统中最常见的肿瘤，约占所有恶性原发性脑肿瘤的80%。高级别胶质瘤恶性程度高、复发风险大，预后较差，中位生存期仅为12-18个月。虽然增强磁共振成像（MRI）是胶质瘤的标准诊断影像学方法，但在评估复发性胶质瘤时存在局限性，无法区分治疗相关改变与肿瘤进展，且不具备直接治疗功能。近年来影像学技术的进步试图解决部分局限性，其中正电子发射断层扫描（PET）在勾画肿瘤边界和指导复发性胶质瘤治疗方面已取得显著成效。此外，随着核医学诊疗一体化技术的发展，PET示踪剂与治疗药物结合后已超越单纯诊断功能，兼具诊断与治疗双重作用。本综述将探讨诊疗一体化技术在复发性胶质瘤诊治中日益深入的应用，并分析其对患者生活质量与功能恢复的影响。
肿瘤(癌症)患者之家